List of Excipients in Branded Drug EVEKEO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	ANHYDROUS CITRIC ACID
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	CELLULOSE, MICROCRYSTALLINE
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	CROSPOVIDONE
Azurity Pharmaceuticals Inc	EVEKEO ODT	amphetamine sulfate	24338-031	DIBUTYL SEBACATE

Generic Drugs Containing EVEKEO

Company	Ingredient	NDC	Excipient
Azurity Pharmaceuticals Inc	amphetamine sulfate	24338-022	CELLULOSE, MICROCRYSTALLINE
Azurity Pharmaceuticals Inc	amphetamine sulfate	24338-022	CROSPOVIDONE
Azurity Pharmaceuticals Inc	amphetamine sulfate	24338-022	STEARIC ACID

What are the Most Frequently-Used Excipients in EVEKEO?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	STEARIC ACID

EVEKEO Excipient Strategy and Commercial Opportunities

Last updated: October 10, 2026

EVEKEO is an immediate-release amphetamine sulfate tablet approved for attention-deficit/hyperactivity disorder and narcolepsy. Its excipient strategy is commercially conventional: lactose-based direct compression with standard flow, binding, disintegration, and lubrication functions. The strongest opportunities are not basic reformulation of the existing tablet, but differentiated pediatric delivery, lactose-free positioning, adherence-focused dosage forms, and manufacturing platforms that reduce controlled-substance handling risk.

What is EVEKEO and which excipients are used?

EVEKEO contains amphetamine sulfate, a mixed amphetamine salt active pharmaceutical ingredient, in 5 mg and 10 mg immediate-release tablets. The product is administered orally and is regulated as a Schedule II controlled substance in the United States. The FDA-approved labeling identifies the inactive ingredients used in the marketed tablets. [1]

EVEKEO tablet excipient profile

Excipient	Primary pharmaceutical function	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Supports low-cost tablet manufacture but limits lactose-free positioning
Microcrystalline cellulose	Diluent, dry binder, compression enhancer	Improves tablet strength and manufacturability
Povidone	Binder	Supports granule or powder cohesion
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and blend uniformity
Sodium lauryl sulfate, where present in the approved formulation	Wetting agent	Can improve powder wetting and dissolution behavior

The exact excipient composition, grade, and quantitative levels should be controlled through the applicable FDA labeling, approved chemistry, manufacturing, and controls documentation. Excipient substitution may require a post-approval change assessment, comparative dissolution work, stability testing, and potentially a supplemental filing under FDA post-approval change requirements. [1, 2]

What excipient functions are most important for amphetamine sulfate tablets?

The highest-value formulation attributes are content uniformity, low-dose blend uniformity, rapid disintegration, chemical stability, and controlled-substance containment.

Content uniformity

Amphetamine sulfate is present at a relatively low dose compared with the total tablet mass. This makes blend segregation and assay variability important risks. Particle-size distribution, density matching, geometric dilution, ordered mixing, and low-shear blending can have greater impact than simply increasing binder concentration.

Colloidal silicon dioxide and microcrystalline cellulose can improve flow and reduce segregation, but excessive glidant or lubricant can impair compactibility and dissolution. Magnesium stearate is particularly sensitive to over-lubrication, which can reduce tablet tensile strength and slow wetting.

Disintegration and dissolution

Immediate-release EVEKEO must release amphetamine sulfate promptly. Crospovidone supports rapid tablet breakup, while lactose and microcrystalline cellulose provide soluble and insoluble portions of the matrix. A reformulation program should measure:

• Disintegration time across tablet strengths
• Dissolution in multiple aqueous media
• Assay and related substances
• Tablet hardness and friability
• Blend and content uniformity
• Stability under long-term and accelerated conditions
• Performance after exposure to humidity and temperature excursions

For a generic or line extension, dissolution matching alone is not sufficient. The sponsor must also manage inactive-ingredient safety, manufacturing reproducibility, labeling, and controlled-substance controls.

What excipient strategy could improve EVEKEO?

A practical strategy has four layers: preserve the core immediate-release product, develop a differentiated pediatric platform, remove avoidable excipient constraints, and improve manufacturing security.

1. Maintain the existing tablet as the cost platform

The current lactose-based direct-compression approach is likely to remain the lowest-cost product architecture. It uses widely available excipients and conventional equipment. A manufacturer seeking generic or private-label entry would generally prioritize:

• Robust low-dose blending
• Standardized excipient grades
• Short compression cycles
• High tablet yield
• Low friability
• Stable dissolution after scale-up
• Minimal excipient changes relative to the reference product

This approach has limited differentiation but the lowest technical and regulatory risk.

2. Develop a lactose-free tablet

A lactose-free EVEKEO-equivalent could replace lactose monohydrate with combinations of microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or silicified microcrystalline cellulose.

The commercial case is strongest where prescribers or caregivers avoid lactose, where a product seeks a clean-label position, or where the manufacturer wants a broader platform for pediatric dosage forms. The principal technical risks are tablet size, mouthfeel, dissolution, hardness, and blend segregation.

Mannitol can improve palatability and cooling sensation in orally disintegrating products. Dibasic calcium phosphate can increase density and compressibility but may alter dissolution and may be less attractive for some pediatric formulations. Starch-based systems can support disintegration but may increase moisture sensitivity.

3. Build a pediatric-friendly platform

Pediatric ADHD treatment creates the clearest excipient-led opportunity. Many children have difficulty swallowing conventional tablets, while caregivers value dose flexibility and predictable administration.

Potential formats include:

• Orally disintegrating tablets
• Mini-tablets
• Sprinkle capsules
• Taste-masked multiparticulates
• Oral powders for reconstitution
• Low-volume oral liquids
• Scored tablets with improved dose subdivision

Each format has a different regulatory and commercial profile. An orally disintegrating tablet can command a premium if it provides rapid disintegration, acceptable taste, and stable dose delivery without water. A liquid offers flexible dosing but introduces preservative, microbial, packaging, dosing-device, and controlled-substance diversion issues.

A sprinkle formulation could improve administration without creating a liquid product. Taste masking would likely require polymer coating, ion-exchange technology, lipid coating, or a multiparticulate matrix. Those systems can create new manufacturing and intellectual-property positions, but they also increase process complexity.

What formulations are commercially attractive for EVEKEO?

Orally disintegrating tablets

An ODT is the most direct reformulation opportunity. The excipient system could use mannitol as a primary diluent, crospovidone or croscarmellose sodium for rapid disintegration, low levels of flavor and sweetener, and a lubricant compatible with rapid wetting.

The central challenges are taste and dose loading. Amphetamine sulfate has an unpleasant taste profile, and masking the drug without slowing release can require specialized excipient systems. ODTs also have higher sensitivity to moisture and mechanical damage than conventional tablets.

A commercially viable ODT would need:

• Disintegration generally compatible with ODT expectations
• Acceptable taste without excessive sweetener
• Adequate mechanical strength
• Child-resistant packaging
• Moisture-protective packaging
• Stable dose uniformity
• Clear instructions for administration and storage

Sprinkle or multiparticulate dosage form

Multiparticulates can provide swallowing flexibility and potentially support taste masking. They may also allow dose titration through capsule strengths or sachets. The main risk is that coating or matrix systems can unintentionally create modified-release behavior. For an immediate-release amphetamine product, the release profile must remain consistent with the intended clinical use.

Oral liquid

An oral solution or suspension could address patients who cannot swallow tablets. Its commercial value would depend on dosing accuracy, taste, preservative system, stability, and diversion controls. A liquid also increases the risk of medication errors because caregivers must measure volume rather than administer a fixed tablet.

The strongest liquid opportunity would likely be a low-volume, taste-masked, unit-dose product with a calibrated oral syringe and tamper-evident packaging.

Low-dose mini-tablets

Mini-tablets can provide flexible pediatric dosing while preserving solid dosage-form stability. They can be packaged in capsules or sachets and administered with soft food if labeling permits. The main development issue is content uniformity at very low unit weights. The manufacturing process must control segregation, electrostatic charging, and tablet-to-tablet weight variation.

How strong is the excipient intellectual-property opportunity?

Excipient patents alone are unlikely to create a strong barrier around a conventional EVEKEO tablet. The more defensible positions involve the combination of:

• A specific taste-masking architecture
• A defined release profile
• A novel multiparticulate design
• A child-resistant or diversion-resistant delivery system
• A stable liquid or suspension
• A manufacturing process that improves uniformity of a low-dose controlled substance
• A clinically supported administration method

A patent directed only to replacing lactose with mannitol or microcrystalline cellulose would likely face design-around risk. Stronger claims would connect the excipient system to measurable performance, such as rapid disintegration, improved palatability, reduced abuse potential, stable assay under high humidity, or controlled particle release.

Manufacturing and trade-secret barriers

Process know-how may be more valuable than composition patents. Potential trade-secret assets include:

• Blend order and mixing energy
• Excipient particle-size specifications
• Lubrication time
• Environmental humidity limits
• In-process sampling plans
• Tablet dedusting and containment procedures
• Packaging line controls
• Cleaning validation for amphetamine residues

Controlled-substance manufacturing also creates operational barriers. A new entrant must establish DEA registration, inventory controls, security procedures, reconciliation systems, diversion monitoring, and validated destruction processes. These requirements increase the cost and complexity of commercial entry even where formulation IP is limited. [3]

What is the FDA regulatory status of EVEKEO?

EVEKEO is an FDA-approved immediate-release amphetamine sulfate product. Its principal labeled indications are ADHD and narcolepsy. The FDA label includes boxed-warning language addressing abuse, misuse, addiction, serious cardiovascular risks, psychiatric adverse reactions, and other stimulant-related risks. [1]

A reformulated product could pursue different regulatory pathways:

Product strategy	Likely U.S. pathway	Key regulatory issue
Equivalent immediate-release tablet	ANDA under section 505(j)	Pharmaceutical equivalence, bioequivalence, inactive-ingredient justification
New ODT or liquid	505(b)(2) NDA or other applicable NDA pathway	Clinical bridging, formulation differences, delivery-system claims
New abuse-deterrent formulation	NDA pathway with abuse-potential evidence	Human abuse-potential, in vitro and possibly clinical studies
New pediatric dosing format	505(b)(2) or supplemental NDA, depending on sponsor and product	Dose flexibility, administration instructions, pediatric usability

FDA’s inactive-ingredient database can support preliminary excipient screening, but it does not replace product-specific safety and compatibility work. [4]

What Orange Book, patent, and exclusivity issues affect EVEKEO?

EVEKEO is an older active ingredient product, so its commercial protection is more likely to depend on formulation, regulatory status, manufacturing capacity, and distribution than on new chemical entity exclusivity.

Patent and Orange Book status

The relevant questions are:

1. Are any unexpired patents listed for the specific EVEKEO NDA?
2. Do those patents claim the tablet composition, dosage form, method of use, or manufacturing process?
3. Are any listed claims relevant to a proposed ANDA?
4. Has the reference product’s regulatory exclusivity expired?
5. Are competing amphetamine sulfate products approved or pending?

Orange Book patent listings are product- and NDA-specific. A company assessing Paragraph IV exposure must review the current Orange Book entry, patent expiration data, FDA listing history, and litigation docket rather than infer protection from the active ingredient’s age. [5]

Paragraph IV challenge risk

A conventional immediate-release generic would face the greatest risk from:

• A listed formulation patent
• A method-of-use patent covering an approved indication
• A patent covering a specific strength or dosage form
• A pending regulatory exclusivity period
• A reference-listed-drug issue involving product availability

Where no relevant unexpired listed patent or exclusivity remains, the principal entry risks are bioequivalence failure, manufacturing readiness, DEA controls, supply reliability, and commercial price erosion.

Settlement agreements

No settlement analysis should be assumed from the existence of a generic filing. Any relevant agreement would need to be assessed through FDA approval records, federal court dockets, FTC reporting, and the parties’ public disclosures. Settlement terms can affect launch timing, authorized-generic strategy, royalty economics, and supply rights.

Which companies are challenging or competing with EVEKEO?

The competitive field includes several categories:

• Generic amphetamine sulfate tablet manufacturers
• Mixed amphetamine salt products such as immediate-release and extended-release Adderall products
• Methylphenidate immediate-release and extended-release products
• Lisdexamfetamine products
• Nonstimulant ADHD medicines
• Authorized or branded pediatric delivery systems

The most relevant commercial comparison is not only the active ingredient. Prescribers and caregivers compare duration, dose flexibility, administration burden, abuse concerns, availability, insurance coverage, and tolerability.

An EVEKEO reformulation that improves administration could compete against broader ADHD products even if it does not have a pharmacologic advantage. The commercial proposition would be strongest where the product solves a specific treatment problem, such as swallowing difficulty, dose titration, taste, or adherence.

How does EVEKEO compare with competing ADHD stimulant products?

Attribute	EVEKEO immediate-release	Extended-release amphetamine	Methylphenidate products	Nonstimulant products
Dosing flexibility	High	Lower	Varies	Generally lower
Duration	Shorter	Longer	Short or long depending on product	Longer, nonstimulant profile
Excipient opportunity	ODT, liquid, mini-tablet, taste masking	Delivery-system and release-control technology	Similar pediatric opportunities	Capsule, liquid, and adherence formats
Generic pressure	High	High but product-specific	High	Varies
Controlled-substance burden	High	High	High for stimulants	Lower or absent for some products
Key commercial lever	Administration and titration	Duration and adherence	Tolerability and delivery	Nonstimulant treatment positioning

What revenue exposure and launch scenarios exist?

Public sources do not establish a reliable product-level revenue figure for EVEKEO without current company disclosures or commercial prescription data. The commercial scenarios are clearer than the precise revenue estimate.

Scenario 1: Conventional generic tablet

This is the highest-volume, lowest-margin route. Entry can create rapid price erosion, especially if multiple ANDA holders launch. Competitive advantage depends on supply reliability, manufacturing cost, wholesaler access, and pharmacy coverage.

Scenario 2: Premium lactose-free tablet

This offers modest differentiation. It is unlikely to sustain a major premium without strong prescriber adoption or payer support. The product may work as a portfolio extension rather than a stand-alone growth engine.

Scenario 3: Pediatric ODT or sprinkle product

This has the strongest formulation-based opportunity. A differentiated dosage form can support higher net pricing, particularly if it improves adherence and has a distinct regulatory position. Market access remains critical because ADHD medicines are often substituted based on formulary status and pharmacy availability.

Scenario 4: Oral liquid

This could address a narrower but clinically meaningful segment. The product would need strong dosing accuracy, palatability, packaging, and diversion controls. The development and commercialization cost would be higher than for a conventional tablet.

What geographic opportunities exist?

The United States is the most defined market because EVEKEO is FDA approved and amphetamine products have established clinical use. Expansion into other jurisdictions would require separate assessment of:

• Local approval status for amphetamine sulfate
• Controlled-substance scheduling
• Import and manufacturing permits
• Pediatric labeling requirements
• Allowed excipient standards
• Local bioequivalence rules
• Packaging and serialization requirements
• Reimbursement and stimulant prescribing restrictions

European and other international markets may have more restrictive amphetamine controls or different treatment preferences. A global excipient platform should therefore use internationally accepted grades and avoid unnecessary excipients with region-specific labeling or safety constraints.

Key Takeaways

• EVEKEO is an immediate-release amphetamine sulfate tablet used for ADHD and narcolepsy.
• Its existing excipient system is conventional and optimized for low-cost tablet manufacture.
• The main formulation weaknesses are limited pediatric administration flexibility and the use of lactose.
• The strongest commercial opportunities are ODT, sprinkle multiparticulates, mini-tablets, and carefully designed oral liquids.
• Excipient substitution alone is unlikely to create a durable patent barrier.
• Stronger IP would combine excipient selection with taste masking, release performance, stability, dosing accuracy, or manufacturing controls.
• Generic entry risk is driven by Orange Book listings, ANDA status, bioequivalence, DEA controls, supply reliability, and price erosion.
• A premium reformulation needs a clear administration or adherence benefit to compete against low-cost amphetamine and methylphenidate products.

FAQs

Can EVEKEO be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, starch, dibasic calcium phosphate, or combinations of these excipients. The reformulated product would require comparative quality, dissolution, stability, and regulatory assessment.

Is an EVEKEO liquid commercially attractive?

It can address patients who cannot swallow tablets, but the product would face higher development costs, taste-masking requirements, dosing-error risk, preservative challenges, and controlled-substance security requirements.

Would an EVEKEO ODT qualify for new patent protection?

Potentially, but a defensible patent would need claims directed to a specific formulation, taste-masking system, performance profile, or manufacturing process. A generic lactose-to-mannitol substitution would have limited standalone strength.

What is the main excipient risk in a low-dose amphetamine tablet?

Blend segregation and content-uniformity failure are primary risks. Particle-size distribution, density, flow, mixing sequence, electrostatic behavior, and lubrication conditions require tight control.

Can EVEKEO compete with extended-release ADHD products through excipients alone?

No. Excipient changes can improve administration and adherence, but they do not replicate extended-release pharmacokinetics without a separate release-control design, regulatory strategy, and clinical or bioequivalence support.

References

1. U.S. Food and Drug Administration. (n.d.). EVEKEO (amphetamine sulfate) tablets prescribing information.
2. U.S. Food and Drug Administration. (2014). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and postapproval changes.
3. U.S. Drug Enforcement Administration. (n.d.). Controlled substance security and regulatory requirements.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.